Health Condition 1: N185- Chronic kidney disease, stage 5
Conditions
Interventions
Intervention1: Desidustat
: 50mg to 150mg oral, given thrice weekly for 24 weeks
Control Intervention1: Erythropoietin: 4000 IU given once weekly to thrice weekly intravenously or subcutaneously for 2
Sponsors
Dr. B. Dharini
Eligibility
Inclusion criteria
Inclusion criteria: 1 Adults aged above 18 years 2 Diagnosed case of chronic kidney disease on dialysis with anemia whose hemoglobin is less than 10 gram per deciliter 3 Not receiving any ESA or HIF PHI therapy for at least four weeks prior to study entry 4 Willingness to provide written informed consent
Exclusion criteria
Exclusion criteria: 1 Anemia due to causes other than CKD for example iron deficiency anemia and vitamin B12 or folate deficiency and hemolytic anemia 2 Recent blood transfusion within 8 weeks prior to enrolment 3 Pregnancy or lactation 4 Active infection at initiation of study. 5 Had history of renal transplant. 6.Uncontrolled hypertension defined as SBP greater than 180 mmg or DBP greater than 100 mmHg at screening visit before dialysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the change in hemoglobin levels from baseline to Week 24 in both desidustat and erythropoietin treatment groups. Timepoint: Every 4 weeks till 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the safety of desidustat and erythropoietinTimepoint: Every 4 weeks till 24 weeks | — |
Countries
India
Contacts
Public ContactB Dharini
Karpagam Faculty of Medical Sciences and Research
Outcome results
None listed